share_log

ANI Pharmaceuticals (NASDAQ:ANIP) Delivers Shareholders Respectable 19% CAGR Over 3 Years, Surging 5.9% in the Last Week Alone

ANI Pharmaceuticals (NASDAQ:ANIP) Delivers Shareholders Respectable 19% CAGR Over 3 Years, Surging 5.9% in the Last Week Alone

ANI Pharmicals(納斯達克股票代碼:ANIP)在3年內爲股東帶來了可觀的19%的複合年增長率,僅在上週就飆升了5.9%
Simply Wall St ·  2023/12/13 05:31

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) shareholders might be concerned after seeing the share price drop 19% in the last quarter. But don't let that distract from the very nice return generated over three years. In fact, the company's share price bested the return of its market index in that time, posting a gain of 68%.

ANI製藥公司(納斯達克股票代碼:ANIP)股東在看到上個季度股價下跌19%後可能會感到擔憂。但是,不要讓這分散人們對三年來產生的非常可觀的回報的注意力。實際上,該公司的股價在當時超過了其市場指數的回報率,漲幅爲68%。

After a strong gain in the past week, it's worth seeing if longer term returns have been driven by improving fundamentals.

在過去一週強勁上漲之後,值得一看的是長期回報是否是由基本面改善推動的。

Check out our latest analysis for ANI Pharmaceuticals

查看我們對ANI Pharmicals的最新分析

To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.

引用巴菲特的話說:“船隻將在世界各地航行,但平地協會將蓬勃發展。市場上的價格和價值之間將繼續存在巨大差異...”通過比較每股收益(EPS)和股價隨時間推移的變化,我們可以了解投資者對公司的態度如何隨着時間的推移而變化。

During three years of share price growth, ANI Pharmaceuticals moved from a loss to profitability. That would generally be considered a positive, so we'd expect the share price to be up.

在三年的股價增長中,ANI Pharmicals從虧損轉爲盈利。這通常會被視爲利好,因此我們預計股價會上漲。

You can see below how EPS has changed over time (discover the exact values by clicking on the image).

你可以在下面看到 EPS 是如何隨着時間的推移而發生的變化(點擊圖片發現確切的數值)。

earnings-per-share-growth
NasdaqGM:ANIP Earnings Per Share Growth December 13th 2023
納斯達克通用汽車公司:ANIP 每股收益增長 2023 年 12 月 13 日

We know that ANI Pharmaceuticals has improved its bottom line lately, but is it going to grow revenue? If you're interested, you could check this free report showing consensus revenue forecasts.

我們知道ANI Pharmicals最近提高了利潤,但它會增加收入嗎?如果你感興趣,可以查看這份顯示共識收入預測的免費報告。

A Different Perspective

不同的視角

It's good to see that ANI Pharmaceuticals has rewarded shareholders with a total shareholder return of 27% in the last twelve months. That's better than the annualised return of 3% over half a decade, implying that the company is doing better recently. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. It's always interesting to track share price performance over the longer term. But to understand ANI Pharmaceuticals better, we need to consider many other factors. For example, we've discovered 3 warning signs for ANI Pharmaceuticals that you should be aware of before investing here.

很高興看到ANI Pharmicals在過去十二個月中向股東提供了27%的總股東回報率。這比五年來3%的年化回報率要好,這意味着該公司最近的表現更好。鑑於股價勢頭仍然強勁,可能值得仔細研究該股,以免錯過機會。長期跟蹤股價表現總是很有意思的。但是,爲了更好地了解ANI Pharmicals,我們需要考慮許多其他因素。例如,我們發現了ANI Pharmicals的3個警告信號,在投資之前,您應該注意這些信號。

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

對於那些喜歡尋找中獎投資的人來說,這份最近有內幕收購的成長型公司的免費名單可能只是門票。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文引用的市場回報反映了目前在美國交易所交易的股票的市場加權平均回報率。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St 的這篇文章本質上是籠統的。我們僅使用公正的方法提供基於歷史數據和分析師預測的評論,我們的文章並非旨在提供財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不會考慮最新的價格敏感型公司公告或定性材料。華爾街只是沒有持有上述任何股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論